medigraphic.com
Colegio de Medicos y Cirujanos República de Costa Rica

2011, Número 596

<< Anterior Siguiente >>

Rev Med Cos Cen 2011; 68 (596)


Esteroides Nebulizados

Flores BA, Alvarado GA

Idioma: Español
Referencias bibliográficas: 66
Paginas: 5-15
Archivo PDF: 577.23 Kb.


RESUMEN

La suspensión de GCS nebulizados, básicamente budesonida, fue introducida en Costa Rica en el año 2003 como una alternativa a la terapia sistémica, para el tratamiento de la exacerbación de asma y EPOC. Se procede a realizar una discusión de los mecanismos de acción (genómicos y no genómicos) de los GCS nebulizados y del particular sistema de conjugación de la budesonida administrada por esta vía. Ello aunado al reducido tamañode las partículas de la suspensión para nebulizar, su farmacoquinética, su alto perfil de seguridad y baja biodisponibilidad sistémica la posicionan como una forma eficaz y segura de usar en dichas exacerbaciones. Se realiza un análisis sobre costo-eficacia de dicha formulación y se sugieren indicaciones y contraindicaciones de la droga administrada. La revisión permiten proponerla como una opción viable en asma y EPOC en crisis.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Adcock,I.M. Glucocorticoid-regulated transcription factors. Pulm Pharmacol Ther. 2001; 141: 211-219.

  2. Astra Pharmaceuticals, Pulmicort Respules data sheet In: ABPI Compendium of data sheets and Summaries of Product Characteristics, London; Datapharm Publications. Ltd, 1999: 131-132.

  3. Astra Zeneca, Pulmicort Respules (budesonide inhalation suspension) prescribing information, Astra Pharamaceuticals, (P, Waybe, Pennsilvania, USA, Aug 2000.

  4. Bakhirenal, L.N.; Jones, KL.; Schatz, M.; Johnson, D.; Chambers, C.D. Organization of teratology Information Services research group. Asthma medication use in pregnancy and fetal growth. J Allergy Clin Immunol. 2005; 116 503-509.

  5. Barnes, P.J.; Adcock,I.M. How do corticosteroids work in asthma?. Ann Intern Med. 2003; 139: 359-370.

  6. Barry, P. W.; O”Callaghan, C. Drug output from nebulizers is dependent of the method of measurement. Eur Respir J. 1998; 12: 463-466.

  7. Bisgaard, H.; Nikander, K.; Munch, E. Comparative study of budesonide as a nebulized suspension vs pressurized metered dose inhaler in adult asthmatics. Respire. Med 1998; 92:44-49.

  8. Brithis guidelines on asthma management: 1995 review and position statement. Thorax. 1997; 52 ( suppl1 ): S1-S21.

  9. Celli, B.R.; MacNee, W.; and committee members. Standars for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004; 23: 932-946.

  10. Center of Disease Control and Prevention. Asthma prevalence and control characteristics by race/ethnicity-United States, 2002. MMWR.Morb Mortal Weekly. 2004; 53: 145-168

  11. Connolly, K.C.; Peake, M.D.; Halpin, D.M.G.; Golightly, L.; Turbitt, M.L. on behalf of Astra Pharmaceuticas Research group. Challenging Current Asthma Treatment Guidelines. Dis Manage Health Outcomes. 2000; 7: 217-225.

  12. Dahlström, K.; Thorsson, L.; Larsson, P.; Nikander, K. Systemic availability and lung deposition of budesonide via three different nebulizers in adult. Ann Allerg Asthm Immunol.2003; 90: 226-232.

  13. Deffebach, M.E.;. Charar, N.B.; Lakshminarayaran, S.; Butler,J. The bronchial circulation: small, but vital attribute of the lung. Am Rev Respir Dis. 1987; 135: 463-486.

  14. Druss, B. G.; Marcus, S. G.; Offson, M.; Tanielian, T.; Elison, L.; Pineus, H.A. Comparing the national economic burden of five chronic conditions Health Aff (Millwood). 2 001; 68: 20: 233-241.

  15. Ediger, D.; Coskyn, F.; Kunt Uzaslan, E.; Gürdal Yüksel, E.; Karadag, M.; Ege, E.; Gözü, O. Clinical effectiveness of nebulized budesonide in the treatment of acute asthma attacks. Tüberküloz ve Toraks Dergis. 2006; 54: 128-136.

  16. Edsbäcker, S.; Brattsand, R. Budesonide fatty acid esterification: a novel mechanism prolonging binding to airway tissue. Ann Allergy Asthma Immunol. 2002; 88: 609-616.

  17. Global Initiative for Bronchial Asthma, 2009. En: www.ginasthma.org Consultado el 26 de enero del 2010.

  18. Global Initiative for Chronic Obstructive Lung Disease 2006. En: www.goldcopd.org Consultado el 5 de abril del 2009.

  19. Global Inititative for Bronchial Asthma. 2006. En: http://www.ginasthma. org. Consultado el 5 de abril del 2009.

  20. Gunen, H.; Hacionlinagil, S.S.; Yelkin, O.; Gulbas, G.; Multin, L.C; In, E. The role of nebulized budesonide in the treatment of exacerbations of COPD. Eur Respir J. 2007; 29: 660-667.

  21. Hansel, T.T.; Barnes, P.J. Introduction: definitions, burden and causation. In: An Atlas of Chronic Obstructive Pulmonary disease.1st Ed. London; Parthenon Publishing Group. 2005: 1-19

  22. Horvath, G.; Zutto, Z.; Torbati, A.; Conner,G.E.; Salathe, M.; Wanner, A. Norepinefrine transported by extraneuronal monoamine transporter in human bronchial arterial smooth muscle cell. Am J Physiol Lung Cell Mol Physiol. 2003; 10: 1152-1158.

  23. Huizdos, K.M.; Jarns, B. Budesonide Inhalation suspension. A review of its Use in Infants, Children and Adults with Inflamatory Respiratory Disorders. Drugs. 2000; 60: 1141-1178.

  24. Ishioka, S.; Terada, M.; Harutha, Y.; Niyama, K.; Hosawa, S: Yamakido, M. Multiple logistic regression analysis of risks factors fot the development of steroid-dependent asthma in the ederly: a comparison with younger asthmatics. Respiration. 2001; 68: 35-40

  25. Jendbro, M.; Johansson, C.J.; Standberg, P.; Falk-Nilsson, H.; Edsbächer, S. Pharmacokinetics of budesonide and its major ester metabolite after inhalation and intravenous administration of budesonide in the rat. Drug Metab Dispos. 2001; 29; 29: 769-776.

  26. Johansson, S.A.; Anderson, K.E.; Battsand,R.; Gruvstad, E.; Hedener, P. Topical and systemic glucocorticoid potencies of budesonide, beclomethasona dipropionate and prednisolona in man. Eur J Respir Dis. Suppl. 1982; 122: 74-78.

  27. Kallen, B.; Rydhstroem, H.; Aberg,, A. Congenital malformations after the use of inhaled budesonide in early pregnancy. Obstet Gynecol. 1999; 93: 392-395.

  28. Kemp, J.P.; Skoner, D.P.; Szefler, S.J.; Walton-Bowenj, K.; Rivera, M. C.; Smith, J.A. Once-daily budesonide inhalation suspension for the treatment of persistent asthma in infants and young children. Ann Allergy Asthma Immunol. 1999; 83: 231-239.

  29. Kim, U.; Beneditt, J.O.; Wise, R.A.; Sharafkhaneh, A. Oxigen Therapy in Chronic Obstructive Pulmonary Disease. Proc Am Thor Soc.2008; 5: 513-518.

  30. Kraft, W. K.;Steiger, B; Beussink, D.; Quiring, J.M.; Fizgerald, N.; Greenberg, H.E.; Waldman, S.A. The Pharmacokinetics of Nebulized Nanocrystals Budesonide suspension in Healthy Volunteers. J Clin Pharmacol. 2004; 67-72.

  31. Kumar, S.D.; Brieva, J.L.; Oanta. I.; Wanner, A. Transient effect of inhaled fluticasone on airway mucosa blood flow in subjects with and without asthma. Am. J. Respir Crit Care Med.2000; 161: 918-921.

  32. Loddenkemper, R.; Sybrecht, GW. Health Care costs of smoking. Eur Respir J. 2000; 16: 1052-1057.

  33. Losel, R.; Wehling, M. Nongenomic actions of steroids hormones. Nat Rev Mol Cell Biol. 2003; 4: 46-56.

  34. Maciejewski, M.L.; Chen, Shih-Yin, Au, D.H. Adult Asthma Disease Management: An Analysis of Studies Approaches Outcomes and Methods. Respir Care. 2009; 54: 878-886

  35. MacIntyre, N.; Huang, Yuh Chin. Acute Exacerbation and Respiratory Failure in Chronic Obstructive Pulmonary Disease. Proc. Am. Thorac. Soc. 2008; 5: 530-535

  36. Maltais, F.; Ostinelli, J.; Borbeau; J.; Tonnel, A.B.; Jacquemet, N;;Haddon, J.; et al. Comparison of Nebulized and Oral Prednisolone with Placebo in the treatment of Acute Exacerbations of Chronic Obstructive Pulmonary Disease. A Randomized Controlled Trial. Am J. Respir Crit Care Med 2002; 165: 690-703.

  37. Manmino, D.M.; D,M.; Homa, D.M.; Akinbami, L.J.; Ford, E.S.; Redd, S.C. Chronic obstructive pulmonary disease. Survillance-United States. 1971-2000. Respir Care. 2002; 47: 1184-1199.

  38. Marcus, P.; Oppenheimer, E.A.; Patel, P.A.; Katz, L.M.; Doyle, J.J. Use of nebulized inhaled corticosteroids among older adult patients: an assessment of outcomes. Ann Allergy Asthma Immunol. 2006, 96: 736-743.

  39. Mellis, C.M.; Peat, J.K.; Woolcock, A.J. The cost of asthma: can it be reduced?. Pharmacoeconomics. 1993; 3: 205-219.

  40. Mendes, E.S.; Pereira, H.; Danta, I.; Duncan, R.C.; Wanner, A. comparative bronchial vasoconstrictive efficacy of inhaled glucocorticoids. Eur Respir J. 2003; 21: 989-993

  41. Miller-Larsoon, A.; Mattson, H.; Hjertberg, E., Dahlbäck, M.; Tunek, A.; Brattsand, R. Reversibility Fatty Acid Conjugation Prolonged Retention of Topically Applied Steroid in Airway Tissue. Drug Metab Dispos. 1998; 26: 623-630.

  42. Mitchell, C.A.; Alpers, J.H.; Morton, S.M.; et al. Comparison of nebulized budesonide with oral prednisolone in the treatment of sever acute asthma ( abstract n° 2437 ). Eur Respir.J. 1995; Suppl. 19; 4905.

  43. Morice, A.H.; Morris, D.; Lawson-Mathew, L. A comparison of nebulized budesonide with prednisolone in the treatment of exacerbations of obstructive pulmonary disease. Clin Pharmaceutical Ther. 1996; 60: 675-678.

  44. Nielsen, K,G.; Bisgaard, H. The Effect of Inhaled Budesonide on Symptoms, Lung Function and Cold Air and Methacoline Responsiveness in 2 to 5 year-old Asthmatic Children. Am J Respir Crit Care Med. 2000; 162: 1500-1506.

  45. Norjavaara, E.; de Verdier, M.G. Normal pregnancy outomes in a population based study including 2.968 pregnant women exposed to budesonide. J Allergy Clin Immunol. 2003; 111: 736-742.

  46. O”Connell, E.J. Review of the Unique Properties of Budesonide. Clin Ther. 2003, 25 ( Suppl C ): C42-C60.

  47. Pahl, A.; Szelenyn, L. Asthma therapy in the new millenium. Inflamm res. 2002; 51: 272-283

  48. Pawels,R.A.; Pederson, S.; Busse, W.W., Jane, W.C.; Chen, J.Z.; Ohlssen, S.; Ullman, A.; Lamm, C.S.; O”Byrne, P.M. on behalf of the START Investigators Group. Early interventions with budesonide in mild persistent asthma: a randomized double blind tiral. Lancet. 2003; 361: 1071-1076.

  49. Pearlman, D.S. Preclinical Propierties of budesonide: translation to the Clinical Setting. Clin Ther. 2003; 25 ( suppl C ): C75-C91.

  50. Rahimi, R.; Nikfar, S.; Abdollahi, M. Meta-analysis finds use of inhaled corticosteroids during pregnancy safe: a systematic meta-analysis review. Hum Exp Toxicol. 2006; 25: 447-452.

  51. Rodrigo, G.J. Inhaled corticosteroids in the treatment of Asthma exacerbation: essential concepts. Arch Bronchoneumol. 2006: 42: 533-540.

  52. Rodrigo, G.J.; Rodrigo, G. Triple Inhaled Drug Protocol for the treatment of Acute Severe Asthma. Chest. 2003; 123

  53. Rodrigo, J.; Rodrigo, G. Corticosteroids in the emergency department therapy of acute adult asthma: an evidence- based evaluation. Chest. 1999; 116: 285-295

  54. Rowe, B.H.; Spooner, C.D.; Duchareme, F.M.; et al.Early emergency department treatment of acute asthma with systemic corticosteroids ( Cochrane Review ). In: The Cochrane Library Issue 1.Oxford, U.K: Update Software, 2002.

  55. Ruff, L.K.; Volmer, T.; Nowak, D.; Meyer, A. The economic impact of smoking in Germany . Eur Respir J. 2000; 16: 385-390.

  56. Selroos, O.; Edsbäcker, S.; Hultquist, C. Once-Daily Inhaled Budesonide for the Treatment of Asthma: Clinical Evidence and Pharmacokinetic Explanation. J Asthma. 2004; 41: 771-790.

  57. Selye, H. Correlations between the chemical structure and the pharmacological actions of the steroids. Endocrinology. 1942; 30: 437-453.

  58. Stellato, C. Post-transcriptional and Nongenomic Effect of Glucocorticoids Proc Am Thorac Soc. 2004; 1: 225-263

  59. Sullivan, SD.; Ramsey, S.D.; Lee, T.A. The economic burden of COPD. Chest. 2000; 117: 55-59.

  60. Szefler,S.J.; Eigen, H. Budesonide inhalation suspension: A nebulized corticosteroid for persistent asthma.. J Allergy Clin Immunol. 2002; 109: 729-742.

  61. Volovitz, B. Inhaled Budesonide in the management of acute worsening and exacerbations of asthma: A review of the evidence. Respir Med. 2006; 100: 1-11.

  62. Wales, D.; Makker, H.; Kane, J.; McDowell, P.; O”Driscoll. B.R. Systemic Bioavailibility and Potency of High-Dose Inhaled Corticosteroids: A Comparison of Four Inhaler Device and Three Drugs in Health Adults Volunteers. Chest. 1999; 115: 1278-1284.

  63. Wanner, A., Horvath, G.; Brieva, J.L.; Kuniar, S.D.; Méndez, F.S. Nongenomic actionof glucocorticoids on the airway vasculature y asthma. Proc Am Thorac Soc. 2004; 1: 235-238.

  64. Wilson, A.M.; Mcfarlane, L.C.; Lipworth; B.J. Systemic bioactivity profiles of oral prednisolone and nebulized budesonide in adults asthmatics. Chest. 1998; 114: 1022-1027.

  65. Zetterström, O.; Buhl, R.; Mellem, H.; Andersson, F. The whole story: treatment outcomes with Symbicort. Respir Med. 2002; 96 ( Suppl-A ): 529-535-

  66. Zhu, Y.; Rice, C.D.; Pang, Y.; Pace, M.;Thomas, P. Cloning , expression, and characterization of a membrane progestin receptor and evidence it is an intermediaryin mitotic maturation of fish oocystes. Proc Natl Acad Sci. U.S.A.; 2003; 100: 2231-2236




2020     |     www.medigraphic.com